PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.34%
EBIT growth above 1.5x AVXL's 11.33%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
30.35%
Operating income growth above 1.5x AVXL's 11.33%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
30.26%
Net income growth at 50-75% of AVXL's 45.16%. Martin Whitman would question fundamental disadvantages in expenses or demand.
30.58%
EPS growth at 50-75% of AVXL's 47.29%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
33.88%
Diluted EPS growth at 50-75% of AVXL's 49.43%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
0.94%
Share reduction more than 1.5x AVXL's 5.90%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
5.92%
Diluted share count expanding well above AVXL's 10.38%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
10.50%
OCF growth under 50% of AVXL's 66.21%. Michael Burry might suspect questionable revenue recognition or rising costs.
10.43%
FCF growth under 50% of AVXL's 66.21%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10668.67%
Negative 10Y OCF/share CAGR while AVXL stands at 74.32%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
79.98%
5Y OCF/share CAGR above 1.5x AVXL's 32.11%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
60.25%
3Y OCF/share CAGR above 1.5x AVXL's 0.63%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-3178.86%
Negative 10Y net income/share CAGR while AVXL is at 80.82%. Joel Greenblatt sees a major red flag in long-term profit erosion.
82.89%
5Y net income/share CAGR similar to AVXL's 90.18%. Walter Schloss might see both on parallel mid-term trajectories.
76.87%
3Y net income/share CAGR 1.25-1.5x AVXL's 56.47%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
496.60%
10Y equity/share CAGR above 1.5x AVXL's 151.76%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
159.22%
Below 50% of AVXL's 2487.21%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-89.45%
Negative 3Y equity/share growth while AVXL is at 135.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
Negative asset growth while AVXL invests at 15.30%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-43.72%
We have a declining book value while AVXL shows 8.66%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
14.13%
Debt growth of 14.13% while AVXL is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
-30.15%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-30.87%
We cut SG&A while AVXL invests at 17.76%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.